Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

Gelijkaardige items

• Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
  door: Giovannetti, E, et al.
  Gepubliceerd in: (2011)
• In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
  door: Mey, V, et al.
  Gepubliceerd in: (2006)
• Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
  door: Takezawa, K, et al.
  Gepubliceerd in: (2011)
• Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
  door: Steen, Nele Van Der, et al.
  Gepubliceerd in: (2017)
• Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
  door: Nannizzi, Sara, et al.
  Gepubliceerd in: (2009)